Medical AISURMOUNT-1: tirzepatide for obesity - the headline trial.
SURMOUNT-1 was the pivotal phase 3 trial of tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight without diabetes. Mean weight reductions over 72 weeks reached about 15%, 19.5%, and 20.9% across the three doses.
SURMOUNT-1 was the pivotal phase 3 trial of tirzepatide for weight management. Tirzepatide is a single molecule that activates two incretin receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). The trial enrolled adults with obesity, or overweight with at least one weight-related complication, who did not have type 2 diabetes.[1,2]
About 2,539 participants were randomized 1:1:1:1 to once-weekly subcutaneous tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks, which included a roughly 20-week dose-escalation period starting at 2.5 mg and stepping up every four weeks.[1,2] The dose escalation is central to tolerability, not just an administrative detail.
For the treatment-regimen estimand, mean weight reductions at 72 weeks were 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo.[1] The dual GIP/GLP-1 mechanism produced weight loss approaching what had previously been associated mainly with bariatric surgery.
What was tested
All participants received lifestyle counseling; tirzepatide or placebo was added on top. Reported percentages depend on the estimand: the treatment-regimen estimand (which reflects outcomes regardless of whether participants stayed on drug) gives 15.0%, 19.5%, and 20.9%, while the efficacy estimand reported in the press materials is higher.[1] When quoting a number, name the estimand.
What the trial showed
Beyond mean weight change, large proportions of participants reached categorical thresholds: a clear majority achieved at least 5%, 10%, and 15% reductions, with response rising by dose.[1] The most common adverse events were gastrointestinal (nausea, diarrhea, constipation, vomiting), generally mild to moderate and concentrated during dose escalation, which is why the slow titration matters.[1]
SURMOUNT-1 at a glance. Treatment-regimen estimand shown; read the full paper for the efficacy estimand and safety detail.
| Element | SURMOUNT-1 | Note |
|---|---|---|
| Population | Obesity, or overweight with complication; no diabetes | ~2,539 randomized [1,2] |
| Intervention | Tirzepatide 5 / 10 / 15 mg weekly vs placebo | 72 weeks; ~20-week escalation [1] |
| Mean weight change | 15.0% / 19.5% / 20.9% vs 3.1% | Treatment-regimen estimand [1] |
| Tolerability | GI events, mostly mild to moderate | Concentrated during escalation [1] |
| Regulatory result | Zepbound approval | FDA, November 8, 2023 [3] |
What it changed
On November 8, 2023, the FDA approved tirzepatide as Zepbound for chronic weight management in adults with obesity, or overweight with a weight-related condition, used with a reduced-calorie diet and increased physical activity.[3]SURMOUNT-1 was a pivotal trial supporting that approval, and Zepbound was the first weight-management agent acting on both the GIP and GLP-1 receptors.
How to read it carefully
SURMOUNT-1 studied people without diabetes; tirzepatide's glycemic evidence comes from the separate SURPASS diabetes program, and weight loss tends to be smaller in people with type 2 diabetes.[1,2] The headline numbers also assume reaching and tolerating the maintenance dose: the dose-escalation schedule and gastrointestinal tolerability shape who gets there and who stays. As with the class, weight regain is expected if treatment stops.
Twenty percent mean weight loss is a real shift in what medical therapy can do, but the estimand and the dose matter when you quote it.- Section synthesis
The library is curated. The product is asked.
The useful question is what the trial population was and which estimand the reported numbers come from. Ask, and read the figures against your patient.
This explainer is verified against the cited primary sources. Confirm the SURMOUNT-1 estimand-specific results, population, and the current Zepbound label against the cited sources before clinical application.
Medical AI returns evidence-grounded answers backed by real citations. It is a reference tool, and these terms describe how it should and should not be used.
01 Educational purpose
Medical AI is an information and reference tool intended for educational use only. The answers it returns are not medical advice, diagnosis, or treatment. Always consult a qualified doctor or healthcare professional with any question concerning a medical condition.
02 Professional use
Medical AI is designed for use by practicing clinicians. It is not intended for direct patient use and is not a substitute for professional clinical judgment. Apply your own training and current guidelines to every decision an answer informs.
03 Privacy and data
We do not collect, store, or process personally identifiable patient information (PHI or PII). Do not enter names, dates of birth, medical record numbers, or any other patient identifiers into the composer.
04 Information currency
Medical knowledge evolves rapidly. Citations carry their publication date, so consult the primary source and the most recent clinical guideline before acting on anything material.